New Approval Strengthens Top Spot For AstraZeneca's Tagrisso
Gets EU Nod for Early-Stage NSCLC
Executive Summary
Competition may be on the horizon but Tagrisso's position as standard of care for EGFR-mutated NSCLC looks solid, not least after a thumbs-up in the EU for the adjuvant treatment of adults with early-stage disease.
You may also be interested in...
AstraZeneca Focuses On COVID-19 Antibody Approach After Year Of Vaccine Headwinds
During its fourth quarter earnings call, the UK-based major expressed hopes that its prophylactic antibody approach would fare better after its COVID-19 jab faced several obstacles in developed markets last year.
J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers
The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.
EQRx's Aumolertinib May Be A Serious Competitive Contender For Tagrisso
The price of aumolertinib will be "radically lower" than what has become commonplace for cancer medicines, president Melanie Nallicheri told Scrip.